摘要:
Organische Verbindungen, insbesondere Farbstoffe und Vorprodukte werden mit Sauerstoff oder sauerstoffhaltigen Gasen oxidiert, wobei über die Sauerstoffkonzentration im Abgas die Oxidationsreaktion gesteuert wird.
摘要:
Novel antitumor sulfonamide and sulfonic ester derivatives each having a tricyclic hetero ring, represented by general formula (I), and a process for producing the same, wherein G represents a 5- or 6-membered aromatic ring; L represents O or NR1, wherein R1 represents hydrogen or lower alkyl; and M represents a tricyclic structure selected from the members (a), (b), (c), (d), (e), (f), wherein rings A and B represent each a 5- or 6-membered unsaturated ring; X represents NR2 (wherein R2 represents hydrogen or lower alkyl) or NHCO; Y represents O, S(O)¿n?, CR?3R4¿, CO, NR?5, CHR6CHR7, CR8=CR9, NR10¿CO, N=CR?11, OCHR12¿, S(O)¿n?CHR?13 or NR14CHR15¿; and Z represents N or CR16, wherein n represents 0, 1 or 2; R?3-R13, R15 and R16¿ represent each hydrogen or lower alkyl; and R14 represents hydrogen, lower alkyl or lower acyl.
摘要:
The object of the present invention addresses a problem of providing a novel hydrogen storage material containing a metal-organic framework that can effectively store hydrogen. Hydrogen can be effectively stored by use of a hydrogen storage material containing a metal-organic framework, the metal-organic framework comprising a carboxylate ion of formula (I) and a multivalent metal ion, wherein the carboxylate ion and the multivalent metal ion are bound to each other. (In formula (I), X is an unsubstituted or substituted C2-C20 alkyl group, an unsubstituted or substituted alkenyl group, an unsubstituted or substituted alkynyl group, an unsubstituted or substituted alkoxy group, an unsubstituted or substituted alkenyloxy group, an unsubstituted or substituted alkynyloxy group, a benzyloxy group, an unsubstituted or substituted alkylsulfanyl group, an unsubstituted or substituted alkenylsulfanyl group, an unsubstituted or substituted alkynylsulfanyl group, an unsubstituted or substituted alkylamino group, an unsubstituted or substituted dialkylamino group, an unsubstituted or substituted alkenylamino group, an unsubstituted or substituted dialkenylamino group, an unsubstituted or substituted alkynylamino group, an unsubstituted or substituted dialkynylamino group, a phenyl group, a sulfanyl group or an unsubstituted or substituted alkoxycarbonyl group.)
摘要:
The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitor, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.
摘要:
Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):
摘要:
The aim of the invention is to provide a method for preparing carboxylic acid derivatives by aromatic nucleophilic substitution, in which a carboxylic acid derivative having a single carboxyl functional group, or one of the salts thereof, said carboxylic acid derivative having, in the ortho position of the carboxyl functional group, a leaving group, which is preferably an atom of fluorine or of chlorine or an alkoxy group, chiral or not, preferably a methoxy group, said carboxylic acid derivative not being substituted by an electroattractive group other than the leaving group if any; is reacted with a reactant MNu, where M is a metal and Nu is a nucleophile, chiral or not, said aromatic nucleophilic substitution reaction being carried out without a catalyst and without a step of protecting/deprotecting the acid functional group of the starting compound.
摘要:
The present invention relates to a method for preparing aromatic carboxylic acid derivatives by nucleophilic aromatic substitution, which involves reacting an aromatic carboxylic acid derivative supporting only one carboxyl function, or one of the salts thereof, said carboxylic acid derivative supporting, orthogonally to the carboxyl function, a splitting group which is an atom of fluorine or chlorine or an alcoxy group, chiral or otherwise and, in the latter case, a methoxy group is preferred; said carboxylic acid derivative being substituted by at least one electro-attractive group other than the splitting group, preferably by a fluorine atom, with a MNu reagent, wherein M is a metal and Nu is an optionally chiral nucleophile, said nucleophilic aromatic substitution reaction being carried out without a catalyst and without a step of protecting/unprotecting the acid function of the initial compound, said method being selective in that the reaction leads to the formation of ketone derivatives in a very minority fashion during the reaction.
摘要:
A compound of the present invention and pharmaceutically acceptable salts thereof are represented by the following general formula (1). (1) (In the formula (1), the definitions of R1, R2, R3, R4, R5, R6, Q, R8 and R9 are the same as those defined in the description.)
摘要:
Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.